

Opportunity Title: FDA Pharmacovigilance Fellowship

Opportunity Reference Code: FDA-CDER-2022-0785

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2022-0785

How to Apply *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@oraui.org. Please include the reference code for this opportunity in your email.

Application Deadline 8/31/2022 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.

A research opportunity is currently available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Surveillance and Epidemiology (OSE)/Office of Pharmacovigilance & Epidemiology (OPE) located in Silver Spring, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.

This project aims to better understand the landscape of enhanced pharmacovigilance (EPV) requested by FDA and its implications for pharmacovigilance practices. For most marketed products, routine pharmacovigilance is sufficient for post marketing safety surveillance. However, in certain instances, safety concerns requiring further characterization may emerge before approval or after a product is marketed for which EPV may be appropriate.

Under the guidance of the mentor, the participant will learn to collect, organize, and analyze safety data and clinical review information from the various databases in CDER. The participant will also gain an understanding of regulatory practices for surveillance of post-marketing data which is used to identify safety signals and inform agency actions.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be



ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

 GET IT ON
Google Play

 Download on the
App Store

Opportunity Title: FDA Pharmacovigilance Fellowship

Opportunity Reference Code: FDA-CDER-2022-0785

renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should be currently pursuing or have received a master's or doctoral degree in one of the relevant fields (e.g. pharmacy, public health, epidemiology, bioinformatics). Degree must have been received within the past five years.

- Eligibility Requirements**
- **Degree:** Master's Degree or Doctoral Degree received within the last 60 months or currently pursuing.
 - **Discipline(s):**
 - **Life Health and Medical Sciences** ([48](#) 👁)
 - **Other Non-Science & Engineering** ([2](#) 👁)
 - **Social and Behavioral Sciences** ([1](#) 👁)

Affirmation Have you lived in the United States for at least 36 out of the past 60 months? (36 months do not have to be consecutive.)